Predictors for prophylactic antithrombotic prescribing in ischaemic heart disease and the impact of national guidelines

Author： Fijn R.   Stuurman-Bieze A.G.G.   van den Berg P.B.   Brouwers J.R.B.J.   de Graeff P.A.   de Jong-van den Berg L.T.W.  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.56, Iss.9-10, 2000-12, pp. : 739-746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Household Income Losses Associated With Ischaemic Heart Disease For US Employees

By Herrin J.  

PharmacoEconomics, Vol. 17, Iss. 3, 2000-03 ,pp. : 304-314

Adis International

Access to resources Recommend Favorite

Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease

By Rosendorff Clive  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1535-1541

Informa Healthcare

Access to resources Recommend Favorite

NICE decisions on treatment of ovarian cancer and ischaemic heart disease released

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 263, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Abciximab: An Updated Review of its Use in Ischaemic Heart Disease

By Foster R.H.   Wiseman L.R.  

Drugs, Vol. 56, Iss. 4, 1998-10 ,pp. : 629-665

Adis International

Access to resources Recommend Favorite

Secondary Prevention in Coronary Heart Disease: Goal Achievement and Drug Prescribing

By Giverhaug Trude   Bruland Christine   Trovik Thor  

Pharmacy World and Science, Vol. 27, Iss. 6, 2005-12 ,pp. : 472-474

Springer Publishing Company

Access to resources Recommend Favorite